INCYTE CORP

Incyte’s Q2 2026 earnings boost revenue & earnings, driving stock to a 52‑week high thanks to Jakafi growth, Opzelura CMS gains and a strong pipeline outlook.

Incyte’s latest executive option exercises reveal a strategic focus on TSR‑linked incentives and retention, hinting at confidence in growth while spotlighting dilution risks and competitive dynamics.

Incyte’s Latarcibart, a once‑monthly subcutaneous antibody, cut bleeding rates by 76% in all VWD subtypes, offering a safer, needle‑free alternative to IV factor replacement.

Explore how changing reimbursement models and operational challenges are reshaping pharma equity and the viability of high‑cost therapies like CAR‑T and gene editing.

IncYTE Corp. sees mixed week: first‑half rally driven by new product pipeline and partnership wins, followed by a pullback amid market volatility; investors weigh steady valuation, incremental revenue growth, and R&D focus against pricing pressures …

Incyte’s EMA approval of Opzelura, a steroid‑free topical JAK inhibitor, offers a safe, effective alternative for moderate atopic dermatitis and could reshape Europe’s dermatology market.

Incyte’s EMA approval of Opzelura offers a steroid‑free, JAK‑inhibitor cream that swiftly relieves itch in moderate atopic dermatitis, boosting Incyte’s dermatology revenue and patient outcomes.

Incyte’s Minjuvi plus lenalidomide gains Japanese approval for relapsed or refractory DLBCL, delivering durable 58‑60% response rates with manageable safety and boosting treatment options for patients ineligible for stem‑cell transplant.

Incyte’s latest clinical data show Tafasitamab and Zilurgisertib could hit $300M+ revenue by 2028, driving strong M&A interest and reshaping oncology and rare‑disease markets.

Incyte’s new Phase‑II/III data shows INCA033989 and tafasitamab + lenalidomide + R‑CHOP significantly improve outcomes for myelofibrosis, ET and high‑risk B‑cell lymphoma, offering promising efficacy, safety, and competitive pricing for payers and p…